Merck & Co., Inc. - Investor Resources - Contact Us

Contact Us

Contact Information for Investors

Institutional Investors and Analysts should contact:

908 740-1 INV (908 740-1468), Monday - Friday, 8:30 a.m. - 4:00 p.m., ET

Sign up for Email Alerts

Contact Information for Stockholders

Call 800-522-9114, Monday - Friday, 8:00 a.m. - 8:00 p.m., ET to:

Verify your holdings
Change your address
Report lost or missing dividends
Transfer stocks or change ownership
Report lost stock certificates

Or write to:

EQ Shareowner Services
1110 Centre Pointe Curve
Suite 101
Mendota Heights, MN, USA 55120-4100

Merck News on Call

Call 800-CALL-MRK (1-800-225-5675) for:

Materials requests (faxed)
Most recent dividend or earnings information
Recent news releases
Information about our annual meeting of stockholders

This number is available 24 hours a day, 7 days a week.

Request Mailed Materials

Transfer Agent

EQ Shareowner Services

Address for Registered Mail/Federal Express

1110 Centre Pointe Curve

Suite 101

Mendota Heights, MN, USA 55120-4100

Copyright © 2009- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

TRUSTe

TRUSTe

Powered By Q4 Inc. 5.142.0.2